How Digital pathology can help to speed-up Biomarkers detection in Pharma Research ?

10<sup>th</sup> Digital Pathology & Al congress : Europe

Carole CHOTARD, PhD Head of the Histopathology Pole NonClinical Safety Unit – Translational Medicine



08/12/2023

# **Servier Pharmaceutical Company**

### Foundation

- > 21400 employees within the Group
- > More than **20%** of our revenue in Research and Development
- > 30 medicines available to patients in over 150 countries
- New R&D Center opened in Feb 2023 (Paris/Saclay Campus) with the Research, Translational Medicine & Clinical departments



#### RESEARCH AND DEVELOPMENT Translational Medicine





SERVIER

## Servier Pharmaceutical Research – Paris Saclay Campus



# Histopathology Pole -> Projects involvement (Nov 2023)



# Histopathology Pole -> Organization (13 team members)

## Head : Carole CHOTARD





RESEARCH AND DEVELOPMENT

+ Daniela APOSTOL (trainee) (2 months)



Translational Medicine

# Histopathology Pole -> Missions

### Main activities

- > DEVELOP AND APPLY Histological and in situ tissue biomarker detection methods (human and animal samples)
- > **SUPPORT** preclinical model characterization
- CHARACTERIZE tissular expression profiles of targets and biomarkers at DNA, RNA or protein levels Preclinical, Pharmaco-Toxicology and Clinical project
- > **DEVELOP AND APPLY** automated Digital Image Analysis
- > ANALYSIS AND EXPERTISE in Pathology (External and internal collaborations)
- IDENTIFY TARGET ORGANS IN PRECLINICAL TOXICOLOGY at tissular levels (Necropsy and Histology) in collaboration with the Toxicological pathologist
- SCIENTIFIC AND TECHNICAL WATCH, technological innovation for the characterization of biomarkers and acceleration of their application in translational research and clinical development





# Histopathology Pole -> Expertises and workflow



## Examples of projects where Digital Pathology is helping us to speed-up Biomarker detection (Machine and Deep-Learning approaches)

#### 1. Chromogenic Immunohistochemistry

- Preclinical model characterization (Visiopharm Software)
- Biomarker detection in multiple Diseases using Tissue Micro Arrays (TMAs) (Visiopharm Software)

#### 2. Multiplex Immunohistochemistry

- Akoya Technology (HALO Software)
- Lunaphore technology (HALO Software)

#### 3. RNAscope

Toxicological biomarker detection (HALO software)

#### 4. Deep-learning approach

- Germinative centers in Human tonsil (Visiopharm Software)
- > Purkinje cells in mouse brain (Visiopharm Software)

#### RESEARCH AND DEVELOPMENT Translational Medicine



## Histopathology pole -> Chromogenic Immunohistochemistry Oncology project

PDAC PDX in mouse

TRT target RNAi anti-marker1

Laurent Rutault Erik Mire

Ventana/Roche

### PDAC PDX in mouse Non TRT **anti-marker1**



PRECLINICAL MODEL CHARACTERIZATION

> Quality evaluation of the H&E sections : Dr Boivin (Human Pathologist)

Quantification

with Visiopharm software

Quantification using Visiopharm software (Machine & Deep Learning approaches)

Translational Medicine

AND DEVELOPMENT

RESEARCH

control treated

## Histopathology pole -> Chromogenic Immunohistochemistry Oncology project

**DISEASE UNDERSTANDING** TARGET IDENTIFICATION AND VALIDATION **Nathalie Ridoux Johann Richard** 

Ventana/Roche Nanozoomer



Marker expression in Human Multi-cancer Tissue Micro Array (TMA)

#### RESEARCH **AND DEVELOPMENT Translational Medicine**



Positive cells density



Speed-up quantification of protein marker using Visiopharm Software

### Histopathology pole -> Multiplex Immunohistochemistry – Oncology project

#### Human tonsil



#### TARGET IDENTIFICATION AND VALIDATION

#### Pancreatic Cancer



DAPI Marker 1 OPAL 480 Marker 2 OPAL 520 Marker 3 OPAL 570 Marker 4 OPAL 690 Marker 5 OPAL 620



Ventana/Roche Phenolmager (Akoya)

#### Graphic of each marker's density on Human Tonsil for validation



Quality evaluation of the H&E sections : Dr Boivin (Human Pathologist)

Quantification of the biomarkers (density, percentage of expression and co-expression) using HALO software with Spatial distribution of the biomarkers in the tumor microenvironment

Collaboration with the Genomics platform for Spatial Transcriptomics



Translational Medicine

AND DEVELOPMENT

RESEARCH

## Histopathology pole -> Multiplex Immunohistochemistry – Immuno-Oncology project LUNAPHORE Team

#### TARGET IDENTIFICATION AND VALIDATION



RESEARCH AND DEVELOPMENT Translational Medicine



## Histopathology pole -> Multiplex Immunohistochemistry – Immuno-Oncology project

PROPATH

#### TARGET IDENTIFICATION AND VALIDATION



 Spatial cell distribution evaluated by quantification (HALO software) (ongoing)



DISTRIBUTION





SPECIAL PATTERNS



#### RESEARCH AND DEVELOPMENT Translational Medicine

#### SERVIER

## Histopathology pole -> RNAscope - Neurosciences project

#### VALIDATION OF TOXICOLOGICAL BIOMARKERS



Marker 1 mRNA

Marker 1 mRNA

#### RESEARCH AND DEVELOPMENT Translational Medicine

SERVIER\*

Sonia Simoes Karine Albinet Nelly Sourioux Erik Mire

Ventana/Roche Nanozoomer

## Histopathology pole -> RNAscope - Neurosciences project

VALIDATION OF TOXICOLOGICAL BIOMARKERS

- > Quality evaluation of the H&E sections and Marker 1 mRNA distribution : Dr Pasello Dos Santos (Toxicologist Pathologist)
- > Speed-up quantification of mRNA marker in several species and organs using **HALO software** (Machine Learning)



H-score = (1x %cells Low) + (2x %cells Medium) and (3x %cells High)

#### SERVIER

Translational Medicine

AND DEVELOPMENT

RESEARCH

**Oracle Bio** 

## Histopathology pole -> Deep learning approach (Visiopharm software)





Automatic detection of germinative centers in human tonsils for all type of stained slides (H&E, IHC, RNAscope, ...)







#### RESEARCH AND DEVELOPMENT Translational Medicine

SERVIER

## Histopathology pole -> Deep learning approach - Neurosciences project





Manual annotation of mouse cerebellum



Automatic detection of Purkinje cells and quantification (Deep learning Visiopharm software) (ongoing)







### Histopathology pole ->Chromogenic Immunohistochemistry – Oncology clinical study

Karine Albinet Nathalie Ridoux Erik Mire

#### **EVALUATE EFFICACY OF A TREATMENT AND TARGET ENGAGEMENT**

Marker A protein expression in AML





### RESEARCH AND DEVELOPMENT

Translational Medicine

- Quality evaluation of the H&E sections : Dr Boivin
- > Quantification of the biomarkers before stratification of patients : Dr Boivin
- No involvement so far of AI in our internal clinical studies



# **Conclusions & Perspectives**



Work closely with pathologists for the quality evaluation of our tissue sections, validation and distribution of the biomarkers in the tissue.

Two aspects of Digital Pathology in our workflow :

1. Computer based virtual slides review by the pathologist instead of a microscope (Slides digitalization, Calopix web application to visualize scanned microscope slides)

2. Artificial Intelligence (AI) techniques : Machine Learning (ML) and Deep Learning (DL) models

Contributions of AI in our workflow :

✓ Reduce variability observed in Manual Pathology and improve biomarker measurement.

✓ Allows more complex analysis of a large amount of data (Multiplex IHC to evaluate expression, co-expression and distribution of several markers)

- Contribution to decrease the amount of tissue requested (multiplex IHC), specially for biopsies
- ✓ Evaluate a bigger amount of biomarkers in Disease Understanding in a shorter time (TMAs, automatic Image Analysis)
- ✓ Use more and more deep-learning approaches in the future

 $\checkmark$  Evaluation of virtual stainings for futures projects to decrease the amount of work and use of tissue.

### AND DEVELOPMENT Translational Medicine







Karine ALBINET



### Mélanie COLLET



Soror GHALI



### Jérémy LAVIGNE



Erik MIRE



Nathalie RIDOUX





Laurent RUTAULT



Sonia SIMOES



Nelly SOURIOUX



Johann RICHARD



Guillaume DARET

IT people



Nadia BONAMOUR



Dr Jean-François BOIVIN Dr Flavia PASELLO DOS SANTOS









# SERVIER

Translational Medicine

AND DEVELOPMENT

RESEARCH

